Barclays PLC Vertex Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

$327 Billion
Q2 2024

Call Options

22 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $13.5 Million - $16.7 Million	34,300 Added 1039.39%	37,600 $17.6 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $856,149 - $936,768	2,100 Added 175.0%	3,300 $1.38 Million
Q4 2023 Feb 15, 2024	BUY	$343.0 - $410.68 $68,600 - $82,136	200 Added 20.0%	1,200 $488,000
Q3 2023 Nov 07, 2023	BUY	$338.18 - $362.46 $338,180 - $362,460	1,000 New	1,000 $348,000
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $5.14 Million - $5.79 Million	18,000 Added 84.91%	39,200 $11.3 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $13.1 Million - $15.4 Million	-59,200 Reduced 73.63%	21,200 $5.53 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $5.26 Million - $6.64 Million	-29,700 Reduced 26.98%	80,400 $17.7 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $9.09 Million - $10.7 Million	48,500 Added 78.73%	110,100 $22.2 Million
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $9.46 Million - $11 Million	45,700 Added 287.42%	61,600 $13.2 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $2.4 Million - $3.2 Million	11,600 Added 269.77%	15,900 $3.76 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $5.16 Million - $6.77 Million	-22,900 Reduced 84.19%	4,300 $1.25 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $14.6 Million - $18.1 Million	-73,200 Reduced 72.91%	27,200 $6.47 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $750,195 - $1.01 Million	-4,500 Reduced 4.29%	100,400 $22 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $398,952 - $449,016	-2,400 Reduced 2.24%	104,900 $17.8 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $1.38 Million - $1.6 Million	-8,400 Reduced 7.26%	107,300 $19.7 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $16.9 Million - $20.1 Million	103,100 Added 818.25%	115,700 $21.3 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $20.2 Million - $25.5 Million	-132,900 Reduced 91.34%	12,600 $2.09 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $3.76 Million - $4.32 Million	22,400 Added 18.2%	145,500 $28 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $13.2 Million - $15.4 Million	90,600 Added 278.77%	123,100 $20.9 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $40.2 Million - $47 Million	-265,500 Reduced 89.09%	32,500 $5.3 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $9.25 Million - $10.5 Million	67,400 Added 29.23%	298,000 $44.7 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $34.2 Million - $37.4 Million	230,600	230,600 $35.1 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

Capital World Investors Los Angeles, CA

26.7M
Shares

$13.4 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$11.5 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.89 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.29 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account